EUVIMEDEUVIMED entdecken
Crossref

Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome

Alberto Cordero, David Escribano, José Mª García-Acuña, Belén Alvarez-Alvarez, Belén Cid-Alvarez, Moisés Rodriguez-Mañero, Rosa Agra-Bermejo, Mª Amparo Quintanilla, Pilar Zuazola, José R González-Juanatey

Thrombosis Research · 2023

DOI: 10.1016/j.thromres.2023.02.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis Research, 2023. Verfasst von Alberto Cordero und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department. Hospital Universitario de San Juan, Alicante, Spain; Unidad de Investigación de Cardiología, Fundación para el Fomento de la I…. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Current evidence supports the efficacy of prolonged dual antiplatelet treatment (DAPT) for patients at high-ischemic risk and low bleeding risk as well as the efficacy and safety of short DAPT in high-bleeding risk (HBR) patients. METHODS: We evaluated patterns of DAPT candidates in all patients discharged in 2 hospitals after an acute coronary syndrome (ACS). Patients categorized in 3 groups: 1) short-DAPT candidates if they met 1 major o 2 minor criteria for HBR, by the 2019 ARC-HBR criteria; 2) prolonged-DAPT candidates if were not HBR and had recurrent ACS, complex percutaneous coronary interventions or diabetes; 3) standard 12 months DAPT if were not include in the previous 2 groups. Major bleeding (MB) was registered according to 3 or 5 of the BARC consortium definitions. RESULTS: We included 8252 patients and 3215 (39 %) were candidates for abbreviated DAPT, 3119 (37.8 %) for prolonged DAPT, and 1918 (23.2 %) for 12 m DAPT. Relevant differences were observed between the 3 categories beyond the bleeding risk. Median follow-up was 57 months. Multivariate analysis identified higher risk of all-cause mortality (HR: 1.96 95 % CI 1.45-2.67; p < 0.001), cardiovascular mortality (HR: 2.10 95 % CI 1.39-3.19; p < 0.011), MACE (HR: 1.69 95 % 1.50-2.02; p < 0.001) and MB (sHR: 3.41 95 % CI 1.45-8.02; p = 0.005) in candidates to short DAPT. Candidates to prolonged DAPT had higher risk of MACE (HR: 1.17 95 % CI 1.02-1.35; p = 0.027). CONCLUSIONS: Almost two thirds of patients discharged after an ACS would be candidates for short or prolonged DAPT and these patients are at higher risk of MACE and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionHumansPlatelet Aggregation InhibitorsPatient DischargePrognosisHemorrhageDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

AntiplateletBleedingDurationMortality

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Cardiology Department. Hospital Universitario de San Juan, Alicante, Spain; Unidad de Investigación de Cardiología, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO…
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Cardiology Department, Complejo Hospital Universitario de Santiago, Santiago de Compostela, Spain.

Förderung

  • Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares

Zitieren

APA

Cordero, A., Escribano, D., García-Acuña, J. M., Alvarez-Alvarez, B., Cid-Alvarez, B., Rodriguez-Mañero, M., Agra-Bermejo, R., Quintanilla, M. A., Zuazola, P., & González-Juanatey, J. R. (2023). Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome. Thrombosis Research. https://doi.org/10.1016/j.thromres.2023.02.008

Vancouver

Cordero A, Escribano D, García-Acuña JM, Alvarez-Alvarez B, Cid-Alvarez B, Rodriguez-Mañero M, et al. Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome. Thrombosis Research. 2023. doi:10.1016/j.thromres.2023.02.008

BibTeX
@article{Cordero2023,
  author = {Cordero, Alberto and Escribano, David and García-Acuña, José Mª and Alvarez-Alvarez, Belén and Cid-Alvarez, Belén and Rodriguez-Mañero, Moisés and Agra-Bermejo, Rosa and Quintanilla, Mª Amparo and Zuazola, Pilar and González-Juanatey, José R},
  title = {Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome},
  journal = {Thrombosis Research},
  year = {2023},
  doi = {10.1016/j.thromres.2023.02.008}
}
Kostenlos starten →